The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses
Standard
The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses. / Ungefroren, Hendrik; Konukiewitz, Björn; Wellner, Ulrich F; Schrader, Jörg; Keck, Tobias.
in: CANCERS, Jahrgang 15, Nr. 1, 160, 27.12.2022.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Editorial › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses
AU - Ungefroren, Hendrik
AU - Konukiewitz, Björn
AU - Wellner, Ulrich F
AU - Schrader, Jörg
AU - Keck, Tobias
PY - 2022/12/27
Y1 - 2022/12/27
N2 - Pancreatic neuroendocrine neoplasms (pNENs) account for approximately 5% of all pancreatic tumors; thus, they constitute the second most common tumor type in the pancreas [...].
AB - Pancreatic neuroendocrine neoplasms (pNENs) account for approximately 5% of all pancreatic tumors; thus, they constitute the second most common tumor type in the pancreas [...].
U2 - 10.3390/cancers15010160
DO - 10.3390/cancers15010160
M3 - Editorial
C2 - 36612156
VL - 15
JO - CANCERS
JF - CANCERS
SN - 2072-6694
IS - 1
M1 - 160
ER -